NeoDynamics

Introducing NeoNavia - a biopsy system for the era of precision medicin in breast cancer diagnosis. #biopsy

[NeoDynamics @NeoDynamicsAB]

Introducing NeoNavia® – The next generation of tissue sampling. With patented pulse technology to ensure optimal needle control and maximum tissue yield. #neonavia #biopsy

[NeoDynamics @NeoDynamicsAB]

As a consequence of the cost reduction plan announced in November, Aaron Wong, CFO will be leaving NeoDynamics by end May 2024. https://t.co/qDkpzRXpe7

[NeoDynamics @NeoDynamicsAB]

Update on NeoDynamics’ financial situation -
The Board and Management of NeoDynamics have secured short-term financing. https://t.co/QnRxh4ayFa

[NeoDynamics @NeoDynamicsAB]

NeoDynamics receives approximately SEK 0.5 million through the exercise of warrants of series T02. Read press release:
https://t.co/9TLtmjJVQg

[NeoDynamics @NeoDynamicsAB]

Our US Team is present at the Radiological Society of North America's (#RSNA2023 ) 109th Scientific Assembly and Annual Meeting in Chicago to show off our #NeoNavia biopsy system!

[NeoDynamics @NeoDynamicsAB]

NeoDynamics Interim Report Jan-Sep 2023. Read press release here: https://t.co/DIL0ooHkoG

[NeoDynamics @NeoDynamicsAB]

The Board of Directors of NeoDynamics has assessed the current financial situation of the company as critical and is in discussions to secure short and long-term financing. Read press release here: https://t.co/DstsfNYPgW

[NeoDynamics @NeoDynamicsAB]

Change to Financial Calendar 2023 - NeoDynamics will release its Interim Report for January-September 2023 on 28 November 2023.
https://t.co/1MsD5oi3YZ

[NeoDynamics @NeoDynamicsAB]

NeoDynamics will release its Interim Report for January-September 2023 on 27 November 2023.

Press release: https://t.co/J2Rw5ToJWx

[NeoDynamics @NeoDynamicsAB]

The exercise period for NeoDynamics warrants of series TO2 Begins today. Press release: https://t.co/GTL1Sg9UwF

[NeoDynamics @NeoDynamicsAB]

Watch our CFO Aaron Wong present at Redeye Medtech & Diagnostics Event (26 September, 2023).
https://t.co/UlLJWLCpct

[NeoDynamics @NeoDynamicsAB]

#NeoDynamics CEO Anna Eriksrud gives an interview with Redeye, providing a status update on the commercialisation and development of the American market.
https://t.co/4CPhDY4II8

[NeoDynamics @NeoDynamicsAB]

Sista dag för handel med BTU i NeoDynamics är den 20 september. Läs pressmeddelandet här:
https://t.co/RnRhLzwX0d

[NeoDynamics @NeoDynamicsAB]

NeoDynamics announces outcome of rights issue https://t.co/ucxnpRzDG9

[NeoDynamics @NeoDynamicsAB]

NeoDynamics publishes supplement to prospectus. https://t.co/9wjum2dZFl

[NeoDynamics @NeoDynamicsAB]

NeoDynamics reaches an important milestone in the US with the receipt of its first commercial order for #NeoNavia. Read the press release here: https://t.co/ptbTANxgg4

[NeoDynamics @NeoDynamicsAB]

The subscription period in #NeoDynamics rights issue begins today.
https://t.co/dVeOLJVUv5

[NeoDynamics @NeoDynamicsAB]

NeoDynamics Interim Report Jan-June 2023
shows promising Feedback from the US. https://t.co/ssucOEkYMP

[NeoDynamics @NeoDynamicsAB]

NeoDynamics publishes a prospectus in connection with the forthcoming rights issue.
https://t.co/P3T6IYL2fr

[NeoDynamics @NeoDynamicsAB]

Takeaways from the presentations of the PULSE study at the Annual Congress of the German Society of Senology in Munich:
- high success rate and low rate of adverse
- high control and precision during needle insertion
- was able to take multiple samples with a single insertion

[NeoDynamics @NeoDynamicsAB]

CEO Anna Eriksrud makes a short presentation of #NeoDynamics and answers questions regarding the rights issue in an interview in collaboration with Uddaaktier on Monday, July 3rd, at 7 p.m. https://t.co/omc9KpqsrD